Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director · President/CEO and Board Chair | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tarsus Pharmaceuticals, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Bobak Azamian Living Trust established April 16, 2018 | 827,991 |
Last balance in matching sequence
After 2026-09-04 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-04 · Sale · Disposed 7,100 · Balance 830,891 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Row 2 · 2026-09-04 · Sale · Disposed 2,900 · Balance 827,991 F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. |
| Common StockSEC Table I · non-derivative | Direct | 33,421 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 33,421 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 9, 2026 20:14 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,900 | $91.27 | $264,683.00 |
DisclosureSEC source: 0001827672-26-000013 · wk-form4_1788984881.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 827,991 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $91.06 to $91.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 20:14 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 7,100 | $90.27 | $640,917.00 |
DisclosureSEC source: 0001827672-26-000013 · wk-form4_1788984881.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 830,891 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $90.00 to $90.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 20:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 10,000 | $80.06 | $800,600.00 |
DisclosureSEC source: 0001827672-26-000011 · wk-form4_1788467407.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 837,991 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.00 to $80.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:09 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,418 | $61.81 | $334,886.58 |
DisclosureSEC source: 0001827672-26-000009 · wk-form4_1782158996.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 847,991 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $61.52 to $62.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:09 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,582 | $61.24 | $280,601.68 |
DisclosureSEC source: 0001827672-26-000009 · wk-form4_1782158996.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 853,409 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $60.51 to $61.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| March 19, 2026 Filed Mar 19, 2026 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 11,964 | $67.00 | $801,588.00 |
DisclosureSEC source: 0001827672-26-000007 · wk-form4_1773961418.xml · nonDerivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,421 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 11,667 | $68.71 | $801,639.57 |
DisclosureSEC source: 0001827672-26-000007 · wk-form4_1773961418.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,385 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 10,972 | $69.42 | $761,676.24 |
DisclosureSEC source: 0001827672-26-000007 · wk-form4_1773961418.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,052 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:24 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 14,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · derivative · entry 6 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,634 Underlying: Common Stock · 14,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. F7 · derivative.expiration_date: RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:24 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 23,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · derivative · entry 5 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,243 Underlying: Common Stock · 23,121 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:24 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 16,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · derivative · entry 4 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,975 Underlying: Common Stock · 16,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:24 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 11,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · derivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:24 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 66,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001827672-26-000005 · wk-form4_1773779081.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 60,776 | $0.00 | $0.00 |
DisclosureSEC source: 0001827672-26-000003 · wk-form4_1773086778.xml · derivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,776 Underlying: Common Stock · 60,776 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 96,723 | $0.00 Strike: $74.90 | $0.00 |
DisclosureSEC source: 0001827672-26-000003 · wk-form4_1773086778.xml · derivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,723 Underlying: Common Stock · 96,723 shares Expires 2036-03-04 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Read SEC document |
| December 24, 2025 Filed Dec 30, 2025 21:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 557 | $83.54 | $46,531.78 |
DisclosureSEC source: 0001827672-25-000007 · wk-form4_1767129970.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 857,991 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $83.14 to $84.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 24, 2025 Filed Dec 30, 2025 21:26 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,443 | $82.41 | $448,557.63 |
DisclosureSEC source: 0001827672-25-000007 · wk-form4_1767129970.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 858,548 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.89 to $82.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:06 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GiftCommon Stock | 51,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001827672-25-000005 · wk-form4_1765227987.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750 F1 · ownership.direct: The Reporting Person transferred 51,885 shares of common stock to the Bobak Azamian Living Trust for no consideration. The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 24, 2025 Filed Sep 26, 2025 20:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 6,000 | $55.37 | $332,220.00 |
DisclosureSEC source: 0001827672-25-000003 · wk-form4_1758917331.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 812,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $55.19 to $55.93. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 6,000 | $50.00 | $300,000.00 |
DisclosureSEC source: 0001819790-25-000110 · wk-form4_1755117154.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 818,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 20:47 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 6,000 | $50.00 | $300,000.00 |
DisclosureSEC source: 0001819790-25-000061 · wk-form4_1743022033.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 824,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024. F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 01:48 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,534 | $50.11 | $427,638.74 |
DisclosureSEC source: 0001819790-25-000055 · wk-form4_1742521708.xml · nonDerivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,635 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 19, 2025 Filed Mar 21, 2025 01:48 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,551 | $47.40 | $405,317.40 |
DisclosureSEC source: 0001819790-25-000055 · wk-form4_1742521708.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,169 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 18, 2025 Filed Mar 21, 2025 01:48 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 7,131 | $46.29 | $330,093.99 |
DisclosureSEC source: 0001819790-25-000055 · wk-form4_1742521708.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,720 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:40 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 23,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000046 · wk-form4_1742348409.xml · derivative · entry 5 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,364 Underlying: Common Stock · 23,121 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:40 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 16,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000046 · wk-form4_1742348409.xml · derivative · entry 4 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,950 Underlying: Common Stock · 16,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:40 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 11,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000046 · wk-form4_1742348409.xml · derivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service. F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:40 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 51,395 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-25-000046 · wk-form4_1742348409.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 59,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000022 · wk-form4_1741382259.xml · derivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,512 Underlying: Common Stock · 59,512 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 90,736 | $0.00 Strike: $44.54 | $0.00 |
DisclosureSEC source: 0001819790-25-000022 · wk-form4_1741382259.xml · derivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,736 Underlying: Common Stock · 90,736 shares Expires 2035-03-04 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 23:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 10,415 | $30.60 | $318,699.00 |
DisclosureSEC source: 0001819790-24-000045 · wk-form4_1710889492.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,456 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 16,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000045 · wk-form4_1710889492.xml · derivative · entry 5 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,925 Underlying: Common Stock · 16,975 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service. F6 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2024, March 15, 2025, March 15, 2026 and March 15, 2027, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 11,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000045 · wk-form4_1710889492.xml · derivative · entry 4 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,599 Underlying: Common Stock · 11,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. F5 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest in equal installments on March 15, 2023, March 15, 2024, March 15, 2025 and March 15, 2026, subject to the Reporting Person's continuous service. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 28,274 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001819790-24-000045 · wk-form4_1710889492.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:57 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 92,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000037 · wk-form4_1710194265.xml · derivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,485 Underlying: Common Stock · 92,485 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027, and 2028, subject to the Reporting Person's continuous service. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 21:57 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 136,947 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001819790-24-000037 · wk-form4_1710194265.xml · derivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,947 Underlying: Common Stock · 136,947 shares Expires 2034-03-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on March 7, 2025, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 22:08 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $20.22 | $161,760.00 |
DisclosureSEC source: 0001827672-23-000050 · wk-form4_1703887719.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 830,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.00 to $20.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 22:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 30,557 | $20.36 | $622,140.52 |
DisclosureSEC source: 0001827672-23-000048 · wk-form4_1703284219.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 838,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $20.10 to $20.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| December 20, 2023 Filed Dec 22, 2023 22:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 9,443 | $19.96 | $188,482.28 |
DisclosureSEC source: 0001827672-23-000048 · wk-form4_1703284219.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 868,663 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $19.09 to $20.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:50 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 200 | $19.28 | $3,856.00 |
DisclosureSEC source: 0001827672-23-000045 · wk-form4_1700257834.xml · nonDerivative · entry 3 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 878,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:50 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,904 | $18.54 | $90,920.16 |
DisclosureSEC source: 0001827672-23-000045 · wk-form4_1700257834.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 878,306 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F4 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $18.27 to $19.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:50 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,896 | $18.01 | $52,156.96 |
DisclosureSEC source: 0001827672-23-000045 · wk-form4_1700257834.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 883,210 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.25 to $18.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| October 18, 2023 Filed Oct 20, 2023 20:41 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $13.24 | $105,920.00 |
DisclosureSEC source: 0001827672-23-000043 · wk-form4_1697834436.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 886,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.00 to $13.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| September 20, 2023 Filed Sep 22, 2023 21:30 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $17.21 | $137,680.00 |
DisclosureSEC source: 0001827672-23-000041 · wk-form4_1695418206.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 894,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $16.74 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 21:12 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $17.23 | $137,840.00 |
DisclosureSEC source: 0001827672-23-000039 · wk-form4_1692997962.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 902,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.00 to $17.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:42 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 99,726 | $20.04 | $1,998,509.04 |
DisclosureSEC source: 0001827672-23-000037 · wk-form4_1689975765.xml · nonDerivative · entry 2 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 910,106 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022 F4 · shares: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $19.73 to $20.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:42 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 4,174 | $19.28 | $80,474.72 |
DisclosureSEC source: 0001827672-23-000037 · wk-form4_1689975765.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,009,832 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022 F2 · shares: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $18.69 to $19.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 20:40 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 9,000 | $17.35 | $156,150.00 |
DisclosureSEC source: 0001827672-23-000035 · wk-form4_1689367221.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,014,006 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $17.24 to $17.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:29 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 8,000 | $18.63 | $149,040.00 |
DisclosureSEC source: 0001819790-23-000048 · wk-form4_1687552162.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,023,006 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $18.35 to $18.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:48 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 9,000 | $18.58 | $167,220.00 |
DisclosureSEC source: 0001827672-23-000033 · wk-form4_1686948523.xml · nonDerivative · entry 1 Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair 10b5-1 filing: Plan reported Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018 Disclosed balance after: 1,031,006 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $18.17 to $18.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.